An Antiretroviral Treatment Interruption (ATI) Study to Evaluate the Impact of Genetically Modified Autologous Cells (AGT103-T) to Suppress Human Immunodeficiency Virus Replication in the Absence of Antiretroviral Therapy
N/A
To test the hypothesis that AGT103-T cells therapy will allow HIV positive ...
Impact of a Short-Term Analytical Treatment Interruption and Re-Initiation of Antiretroviral Therapy on Immunologic and Virologic Parameters in HIV-Infected Individuals
N/A
Background:
The immune system helps the body fight off disease. Most peopl...
Status
Completed
Location
National Institutes of Health Clinical Center
Start Date
2017-07-17
Trial ID
NCT03225118
A Trial to Evaluate the Safety and Tolerability of DV700P-RNA and DV701B1.1-RNA Immunization in Combination With Antiretroviral Analytical Treatment Interruption (ATI) in People Living With HIV for Elicitation of V3-glycan Antibodies
PHASE1
This phase 1 study will evaluate the safety, tolerability, and immune respo...
Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 703/HPTN 081 AMP Study
NA
The purpose of this study is to learn whether having the AMP Study antibody...